The Center for Beta Cell Therapy in Diabetes, coordinator of an international consortium in translational medicine in diabetes, and ViaCyte, Inc., a privately held regenerative medicine company, today announced that a human stem cell-derived product candidate has been...
ImaginAb, Inc., an emerging immuno-oncology imaging company, announced today the enrollment of the first patient in the Phase II clinical trial of ImaginAb’s CD8+ T Cell imaging agent. The trial will enroll metastatic cancer patients and will study the...
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on novel, disease-modifying therapies for neurodegenerative diseases has announced its plans to initiate a Phase III trial to evaluate the efficacy of its lead drug, NB-01, in diabetic...
“It is with great satisfaction we can announce acceptance from the FDA and the Central Ethics Committee to initiate the Xplore trial. Applications to the additional countries are being submitted continuously during January and February. First patient in is...
Pyrrolobenzodiazepine-based antibody drug conjugate targets AXL, a receptor tyrosine kinase highly expressed in solid tumors Lausanne, Switzerland, January 16, 2019 – ADC Therapeutics, an oncology drug discovery and development company that specializes in the...
Email
Text